While life with ALS brings continued disease progression, columnist Kristin Neva is encouraged by signs of renewal outdoors.

The FDA cleared the launch of a Phase 1 clinical trial to test cell therapy XS-228 in people with amyotrophic lateral ...

Columnist Dagmar Munn shares the strategy that helps her get unstuck when she's not feeling motivated. Time is precious with ALS, she says.

A three-drug combination worked better than any of them alone in treating ALS caused by mutations in the SOD1 gene, per a new ...

AMX0114 is an antisense oligonucleotide made to prevent or slow the degeneration of axons, which is a key driver of ALS ...

The first ALS patient has been enrolled in an NIH-funded expanded access program trial evaluating MN-166 (ibudilast).